APA

Bojang K., Milligan P., Pinder M., Doherty T., Leach A., Ofori-Anyinam O., Lievens M., Kester K., Schaecher K., Ballou W. R. & Cohen J. (20091009). Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. : Human vaccines.

Chicago

Bojang Kalifa, Milligan Paul, Pinder Margaret, Doherty Tom, Leach Amanda, Ofori-Anyinam Opokua, Lievens Marc, Kester Kent, Schaecher Kurt, Ballou W Ripley and Cohen Joe. 20091009. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. : Human vaccines.

Harvard

Bojang K., Milligan P., Pinder M., Doherty T., Leach A., Ofori-Anyinam O., Lievens M., Kester K., Schaecher K., Ballou W. R. and Cohen J. (20091009). Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. : Human vaccines.

MLA

Bojang Kalifa, Milligan Paul, Pinder Margaret, Doherty Tom, Leach Amanda, Ofori-Anyinam Opokua, Lievens Marc, Kester Kent, Schaecher Kurt, Ballou W Ripley and Cohen Joe. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. : Human vaccines. 20091009.